The new sensor — expected to launch in the second half of 2025 — will provide easier diabetes management for eligible users.

Tandem Diabetes Care, Inc.’s TNDM impressive international expansion is expected to bolster growth in the upcoming quarters. A robust diabetes market provides a favorable opportunity for the company’s ...

Dexcom has won a clearance from the FDA for its longest-lasting continuous glucose monitor, a 15-day version of its flagship ...

The Global Insulin Pump Market achieved a valuation of $5.90 Billion in 2024 and is anticipated to exceed $14.49 Billion by 2035, reflecting a compounded annual growth rate (CAGR) of 8.55% during the ...

The AID system used in the study was Tandem Diabetes Care's t:slim X2 insulin pump with Control-IQ+ technology, used in conjunction with a Dexcom G6 CGM sensor that can be used with NovoLog or ...

San Diego-based Dexcom submitted its 15-day G7 CGM to the FDA in October 2024. The company says its 15-day G7 also meets ...

a continuous blood glucose sensor that sits on the surface of the skin, an insulin pump strapped to the body, and an infusion patch with a catheter that delivers insulin from the pump. Although ...

AID systems, which pair a glucose sensor with a pump to automate insulin dosing, are covered by Medicare and many private insurers in the U.S. for people with Type 1 diabetes. Tandem currently has ...

Patients were randomly assigned in a 2:1 ratio to either the AID group, which received the t:slim X2 insulin pump with Control-IQ+ technology and a Dexcom G6 sensor, or the control group ...

Modern insulin pumps are self-contained devices that attach to a user’s skin via an adhesive patch, and are responsible for administering insulin as needed. Curious as to what was inside ...